• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277300.
  • 2
    Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005; 2: 17482.
  • 3
    Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH, Vessella RL. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3: 24956.
  • 4
    Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood DP, Jr. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 1999; 5: 24215.
  • 5
    Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009; 15: 67783.
  • 6
    Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010; 46: 11818.
  • 7
    Chambers A, Groom A, MacDonald I. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 56372.
  • 8
    Naumov G, MacDonald I, Weinmeister P, Kerkvliet N, Nadkarni K, Wilson S, Morris V, Groom A, Chambers A. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62: 21628.
  • 9
    Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS 2008; 116: 75470.
  • 10
    Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010; 126: 58998.
  • 11
    Hickson J, Huo D, Vander Griend D, Lin A, Rinker-Schaeffer C, Yamada S. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006; 66: 226470.
  • 12
    Kim H, Vander Griend D, Yang X, Benson D, Dubauskas Z, Yoshida B, Chekmareva M, Ichikawa Y, Sokoloff M, Zhan P, Karrison T, Lin A, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001; 61: 28337.
  • 13
    Lotan T, Hickson J, Souris J, Huo D, Taylor J, Li T, Otto K, Yamada S, Macleod K, Rinker-Schaeffer C. c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip. 1 ovarian cancer metastasis involves growth arrest and p21 up-regulation. Cancer Res 2008; 68: 216675.
  • 14
    Lotan T, Lyon M, Huo D, Taxy J, Brendler C, Foster B, Stadler W, Rinker-Schaeffer C. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol 2007; 212: 38694.
  • 15
    Vander Griend D, Kocherginsky M, Hickson J, Stadler W, Lin A, Rinker-Schaeffer C. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 2005; 65: 1098491.
  • 16
    Yoshida B, Dubauskas Z, Chekmareva M, Christiano T, Stadler W, Rinker-Schaeffer C. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59: 54837.
  • 17
    Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CW. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett 2008; 272: 1222.
  • 18
    Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J. Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. The Prostate 1986; 9: 26181.
  • 19
    Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW. The Dunning model. Prostate 2000; 43: 295302.
  • 20
    Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003; 63: 17316.
  • 21
    Chekmareva MA, Kadkhodaian MM, Hollowell CM, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res 1998; 58: 49639.
  • 22
    Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 8846.
  • 23
    Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57: 8469.
  • 24
    Hamano M, Kuramochi H, Nihei N, Kamiya N, Suzuki H, Igarashi T, Barrett JC, Ichikawa T, Ito H. Mechanisms of metastasis suppression by introduction of human chromosome 10 into rat prostate cancer. Asian J Androl 2002; 4: 1239.
  • 25
    Hosoki S, Ota S, Ichikawa Y, Suzuki H, Ueda T, Naya Y, Akakura K, Igarashi T, Oshimura M, Nihei N, Barrett JC, Ichikawa T, et al. Suppression of metastasis of rat prostate cancer by introduction of human chromosome 13. Asian J Androl 2002; 4: 1316.
  • 26
    Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, Isaacs JT. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 1992; 52: 348690.
  • 27
    Mashimo T, Bandyopadhyay S, Goodarzi G, Watabe M, Pai SK, Gross SC, Watabe K. Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Biochem Biophys Res Commun 2000; 274: 3706.
  • 28
    Mashimo T, Goodarzi G, Watabe M, Cuthbert AP, Newbold RF, Pai SK, Hirota S, Hosobe S, Miura K, Bandyopadhyay S, Gross SC, Watabe K. Localization of a novel tumor metastasis suppressor region on the short arm of human chromosome 2. Genes Chromosomes Cancer 2000; 28: 28593.
  • 29
    Nihei N, Kouprina N, Larionov V, Oshima J, Martin GM, Ichikawa T, Barrett JC. Functional evidence for a metastasis suppressor gene for rat prostate cancer within a 60-kilobase region on human chromosome 8p21-p12. Cancer Res 2002; 62: 36770.
  • 30
    Nihei N, Ohta S, Kuramochi H, Kugoh H, Oshimura M, Barrett JC, Isaacs JT, Igarashi T, Ito H, Masai M, Ichikawa Y, Ichikawa T. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7. Genes Chromosomes Cancer 1999; 24: 18.
  • 31
    Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001; 61: 564451.
  • 32
    Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 4538.
  • 33
    el-Rahman A, Hammouda MA, Fakeir A. Flow cytometric evaluation of erythrocyte response to oxidant stress. Cytometry 1995; 20: 1922.
  • 34
    Krishan A. Effect of drug efflux blockers on vital staining of cellular DNA with Hoechst 33342. Cytometry 1987; 8: 6425.
  • 35
    Szmulewitz RZ, Rinker-Schaeffer CW. Metastatic colonization. In: Schwab M, ed. Encyclopedia of cancer, 2nd edn. New York: Springer, 2009.
  • 36
    Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el H, Garfield S, et al. Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest 2010; 120: 297988.
  • 37
    Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, et al. The current state of preclinical prostate cancer animal models. Prostate 2008; 68: 62939.
  • 38
    Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines–part 2. J Urol 2005; 173: 36072.
  • 39
    Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 2005; 173: 34259.
  • 40
    Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34: 64653.
  • 41
    Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008; 68: 5599608.